Q2 2025 Performance Strong revenue growth from acquisitions, enterprise accounts, and innovative clinical solutions Q2 2025 15.2% Total revenue $2.76 billion 16.9% Adjusted operating income %2 11.5% Adjusted diluted EPS2 $2.62 per share 1 1,3 Company overview Quest is a leader in diagnostic testing insights and information services. Read our Q2 earnings press release on our Investor Relations site. " Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15. ...

[Financial Performance Overview](index=1&type=section&id=Financial%20Performance%20Overview) Quest Diagnostics reported strong Q2 2025 results and raised full-year guidance, reflecting robust growth and operational efficiency [Second Quarter 2025 Performance Highlights](index=1&type=section&id=Second%20Quarter%202025%20Performance%20Highlights) Quest Diagnostics reported strong second-quarter 2025 results, with total revenue increasing by 15.2% to $2.76 billion, driven by a 5.2% rise in organic revenues and contributions from acquisitions. Adjusted diluted EPS grew by 11.5% to $2.62. The company also saw a significant 67.1% year-over-year increase in year-to-date cash provided by operations, reaching $858 million Q2 & H1 2025 Financial Performance vs. 2024 | Metric | Three Months Ended June 30, 2025 | Change vs. 2024 | Six Months Ended June 30, 2025 | Change vs. 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Revenues** | $2,761 million | 15.2% | $5,413 million | 13.7% | | **Reported Diluted EPS** | $2.47 | 21.7% | $4.41 | 17.6% | | **Adjusted Diluted EPS** | $2.62 | 11.5% | $4.83 | 10.0% | | **Cash Provided by Operations** | $544 million | 51.5% | $858 million | 67.1% | | **Requisition Volume** | N/A | 16.3% | N/A | 14.3% | - Growth was driven by demand for innovative clinical solutions, expanded business from enterprise accounts, and contributions from acquisitions[2](index=2&type=chunk) - Productivity gains were realized through the continued deployment of automation and digital technologies across operations[2](index=2&type=chunk) [Updated Full Year 2025 Guidance](index=2&type=section&id=Updated%20Full%20Year%202025%20Guidance) Reflecting strong performance and positive utilization trends, the company has raised its full-year 2025 guidance. The updated forecast anticipates higher net revenues, adjusted diluted EPS, and cash from operations compared to previous estimates Full Year 2025 Guidance Update | Metric | Updated Guidance (Low - High) | Prior Guidance (Low - High) | | :--- | :--- | :--- | | **Net Revenues** | $10.80B - $10.92B | $10.70B - $10.85B | | **Net Revenues Increase** | 9.4% - 10.6% | 8.4% - 9.9% | | **Reported Diluted EPS** | $8.60 - $8.80 | $8.62 - $8.87 | | **Adjusted Diluted EPS** | $9.63 - $9.83 | $9.55 - $9.80 | | **Cash Provided by Operations** | Approx. $1.55B | Approx. $1.5B | [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) The company's Q2 2025 financial statements show revenue growth, increased profitability, and improved cash flow, alongside a strengthened balance sheet [Consolidated Statements of Operations](index=4&type=section&id=Consolidated%20Statements%20of%20Operations) For the second quarter of 2025, net revenues grew to $2.76 billion from $2.40 billion year-over-year. Operating income increased to $438 million, and net income attributable to Quest Diagnostics rose to $282 million, or $2.47 per diluted share, compared to $229 million, or $2.03 per diluted share, in the prior-year period Key Income Statement Data (in millions) | Line Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Revenues** | $2,761 | $2,397 | $5,413 | $4,763 | | **Operating Income** | $438 | $355 | $784 | $655 | | **Net Income Attributable to Quest** | $282 | $229 | $502 | $423 | | **Diluted EPS** | $2.47 | $2.03 | $4.41 | $3.75 | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, Quest Diagnostics reported total assets of $16.0 billion, a slight decrease from $16.2 billion at year-end 2024. Cash and cash equivalents decreased to $319 million from $549 million, while total debt (current and long-term) was reduced to $5.67 billion from $6.22 billion over the same period. Total stockholders' equity increased to $7.27 billion Key Balance Sheet Data (in millions) | Line Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $319 | $549 | | **Total Assets** | $15,969 | $16,153 | | **Total Debt (Current + Long-term)** | $5,673 | $6,217 | | **Total Liabilities** | $8,704 | $9,340 | | **Total Stockholders' Equity** | $7,265 | $6,813 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the first six months of 2025, net cash provided by operating activities significantly increased to $858 million from $514 million in the prior-year period. Net cash used in investing activities was $239 million, primarily for capital expenditures. Financing activities used $854 million, largely due to $1.0 billion in debt repayments and $174 million in dividend payments Cash Flow Summary for Six Months Ended June 30 (in millions) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | **Net Cash from Operating Activities** | $858 | $514 | | **Net Cash used in Investing Activities** | ($239) | ($413) | | **Net Cash used in Financing Activities** | ($854) | ($516) | | **Net Change in Cash** | ($230) | ($415) | - Key uses of cash in financing activities for H1 2025 included **$1,001 million** for debt repayments and **$174 million** for dividend payments[19](index=19&type=chunk) [Notes to Financial Tables](index=7&type=section&id=Notes%20to%20Financial%20Tables) This section details the reconciliation of GAAP to non-GAAP financial measures, explaining key adjustments for a clearer view of underlying performance [Reconciliation of GAAP to Non-GAAP Financial Measures](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) This section provides a detailed reconciliation between reported GAAP results and adjusted non-GAAP figures. Management presents these adjusted measures, which exclude items like restructuring charges, amortization, and certain gains or losses, because they believe it provides a clearer view of underlying business trends and performance [Q2 2025 Reconciliation](index=7&type=section&id=Q2%202025%20Reconciliation) For the second quarter of 2025, reported diluted EPS of $2.47 was adjusted for several items, including restructuring charges, amortization expense, and a gain related to the CARES Act, resulting in an adjusted diluted EPS of $2.62 Q2 2025 GAAP to Non-GAAP EPS Reconciliation | Description | Per Share Impact | | :--- | :--- | | **Reported Diluted EPS (GAAP)** | **$2.47** | | Restructuring and integration charges | $0.04 | | Other charges | $0.19 | | Gains and losses on investments | ($0.01) | | Other gains (e.g., CARES Act) | ($0.30) | | Amortization expense | $0.25 | | Excess Tax Benefits (ETB) | ($0.02) | | **Adjusted Diluted EPS (Non-GAAP)** | **$2.62** | [YTD 2025 Reconciliation](index=8&type=section&id=YTD%202025%20Reconciliation) For the six months ended June 30, 2025, reported diluted EPS of $4.41 was adjusted to $4.83. The adjustments were similar to the quarterly figures, accounting for restructuring, amortization, and other special items over the six-month period YTD 2025 GAAP to Non-GAAP EPS Reconciliation | Description | Per Share Impact | | :--- | :--- | | **Reported Diluted EPS (GAAP)** | **$4.41** | | Restructuring and integration charges | $0.17 | | Other charges | $0.21 | | Gains and losses on investments | ($0.01) | | Other gains (e.g., CARES Act) | ($0.36) | | Amortization expense | $0.51 | | Excess Tax Benefits (ETB) | ($0.10) | | **Adjusted Diluted EPS (Non-GAAP)** | **$4.83** | [Full Year 2025 Guidance Reconciliation](index=9&type=section&id=Full%20Year%202025%20Guidance%20Reconciliation) The company's full-year 2025 guidance for reported diluted EPS of $8.60-$8.80 is reconciled to an adjusted diluted EPS range of $9.63-$9.83 by factoring in estimated full-year impacts from amortization, restructuring, and other special charges and gains Full Year 2025 GAAP to Non-GAAP Guidance Reconciliation | Description | Per Share Impact | | :--- | :--- | | **Diluted EPS (GAAP) Outlook** | **$8.60 - $8.80** | | Restructuring and integration charges | $0.24 | | Amortization expense | $1.03 | | Other charges | $0.27 | | Other gains | ($0.36) | | Gains and losses on investments | ($0.01) | | Excess Tax Benefits (ETB) | ($0.14) | | **Adjusted Diluted EPS (Non-GAAP) Outlook** | **$9.63 - $9.83** | [Explanation of Adjustments](index=9&type=section&id=Explanation%20of%20Adjustments) The adjustments between GAAP and non-GAAP results for Q2 and H1 2025 include several key items. These consist of pre-tax charges for restructuring and workforce reductions, a significant impairment charge on long-lived assets, and a notable pre-tax gain from a CARES Act payroll tax credit - Restructuring and integration charges amounted to **$7 million** for Q2 and **$26 million** for H1 2025, primarily from workforce reductions and integration costs[27](index=27&type=chunk) - A pre-tax impairment charge of **$24 million** was recorded in Q2 2025 on long-lived assets related to the potential exit of a business[27](index=27&type=chunk) - A **$46 million** pre-tax gain was recognized in Q2 2025 from a CARES Act payroll tax credit for employee retention[29](index=29&type=chunk) [Other Information](index=2&type=section&id=Other%20Information) Quest Diagnostics, a leading diagnostic information provider, includes standard forward-looking statements cautioning on potential risks [About Quest Diagnostics & Forward-Looking Statements](index=2&type=section&id=About%20Quest%20Diagnostics%20%26%20Forward-Looking%20Statements) Quest Diagnostics describes itself as a leading provider of diagnostic information services, serving one in three adult Americans and half of U.S. physicians and hospitals. The release also contains standard forward-looking statements, cautioning that actual results could differ materially due to various risks and uncertainties detailed in their SEC filings - Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States[9](index=9&type=chunk) - The report includes a forward-looking statements disclaimer, warning of risks that could cause actual results to differ, such as economic conditions, competitive environment, and changes in government policies[10](index=10&type=chunk)[11](index=11&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) The company announced it will hold a conference call at 8:30 a.m. Eastern Time on July 22, 2025, to discuss the quarterly financial results. Access is available via phone and a live webcast, with a replay available until August 5, 2025 - A conference call to discuss results is scheduled for 8:30 a.m. Eastern Time on July 22, 2025[7](index=7&type=chunk) - A replay of the call will be available by phone and online until midnight Eastern Time on August 5, 2025[8](index=8&type=chunk)

Core Insights - Quest Diagnostics reported a strong second quarter for 2025, with revenues increasing by 15.2% year-over-year, driven by both organic growth and acquisitions [2][6] - The company raised its full-year guidance for 2025 based on positive performance trends and increased demand for its clinical solutions [2][3] Financial Performance - Net revenues for the second quarter reached $2.76 billion, up from $2.40 billion in 2024, marking a 15.2% increase [2][6] - Diagnostic Information Services revenues also grew by 15.7% to $2.70 billion compared to $2.33 billion in the previous year [2][6] - Adjusted diluted EPS for the quarter was $2.62, reflecting an 11.5% increase from $2.35 in 2024 [2][6] - Operating income rose to $438 million, a 23.3% increase from $355 million in the same quarter last year [2][6] Operational Metrics - Requisition volume increased by 16.3%, while organic requisition volume grew by 2.1% [2][6] - Cash provided by operations for the first half of 2025 was $858 million, up 67.1% from $514 million in 2024 [2][6] Updated Guidance - The updated guidance for full-year 2025 includes net revenues projected between $10.80 billion and $10.92 billion, an increase of 9.4% to 10.6% [3] - Reported diluted EPS is now expected to be between $8.60 and $8.80, while adjusted diluted EPS is forecasted to be between $9.63 and $9.83 [3][6]

Core Viewpoint - Quest Diagnostics Incorporated (DGX) is positioned favorably for an upcoming earnings report, with positive trends indicating a potential earnings beat [1][5]. Earnings Estimate Revisions - Recent favorable earnings estimate revisions for Quest Diagnostics suggest a positive outlook, as analysts have raised their estimates just before the earnings report [2][5]. - The Most Accurate Estimate for the current quarter stands at $2.59 per share, slightly above the Zacks Consensus Estimate of $2.57 per share, indicating recent upward revisions by analysts [3]. Earnings ESP and Historical Performance - Quest Diagnostics has a Zacks Earnings ESP of +0.67%, which is a positive indicator heading into earnings season [3]. - Historical data shows that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of delivering positive surprises and have averaged over 28% in annual returns [4]. Investment Consideration - Given the positive earnings estimate revisions and the current Zacks Rank of 3, investors may want to consider Quest Diagnostics as a potential investment ahead of the earnings report [5].

Core Insights - Quest Diagnostics (DGX) is expected to release its Q2 2025 results on July 22, with adjusted EPS of $2.21 in the last quarter, exceeding estimates by 2.79% [1] - The Zacks Consensus Estimate for Q2 2025 revenues is $2.72 billion, reflecting a 13.4% increase year-over-year, while EPS is projected to rise by 9.4% to $2.57 [2] Revenue and Earnings Estimates - Q2 2025 revenue estimates for Quest Diagnostics have increased by 1 cent to $2.57 in the past week [3] - The anticipated revenue growth is driven by the Advanced Diagnostics portfolio and strong performance across key clinical areas [4] Growth Drivers - The core Diagnostics Information Services (DIS) business is expected to see growth from prenatal and hereditary genetic testing, as well as the new HPV self-collection solution [5] - The AD-Detect suite for Alzheimer's risk assessment is likely to contribute to growth through personalized testing approaches [5] - The introduction of the Haystack minimal residual disease (MRD) blood test and large enterprise accounts are expected to further boost Advanced Diagnostics growth [6] Market Access and Partnerships - Revenue growth in Q2 2025 is supported by expanded health plan access with Elevance Health and Sentara Health Plans, effective January 1 [7] - Quest Diagnostics is now part of the Optum Health preferred lab network, enhancing service delivery to over 85,000 physicians [7] Operational Efficiency - The Collaborative Lab Solutions business is anticipated to lead revenue growth in the hospital channel [8] - The company is focusing on productivity gains from recent acquisitions and leveraging automation, robotics, and AI to improve operational efficiency [11] Financial Projections - Quest Diagnostics is projected to achieve 13.4% revenue growth and 9.4% EPS growth in Q2 2025, driven by Advanced Diagnostics and expanded payer access [9] - The DIS revenues are expected to increase by 13.5% year-over-year, with acquisitions contributing 5.8% [10] - Operating income is projected to rise by 13.6% year-over-year in Q2 2025 [11] Earnings Expectations - Quest Diagnostics has an Earnings ESP of +0.67% and a Zacks Rank of 3, indicating a higher chance of beating estimates [12]

Core Viewpoint - Digi Power X Inc. has successfully entered into a securities purchase agreement for the sale of 4,807,693 shares at an offering price of U.S.$3.12 per share, resulting in gross proceeds of approximately U.S.$15 million, which will enhance its financial position and support its growth strategy in AI and digital infrastructure [2][3][9]. Financial Highlights - The offering is expected to close on or about July 22, 2025, subject to regulatory approval [4]. - Post-offering, the company will have over U.S.$30 million in cash and cash equivalents, with no long-term debt [3][9]. - The financing is aimed at solidifying the company's capital position as it transitions from deployment to monetization [4]. Strategic Initiatives - The funds will be utilized to expand the deployment of NeoCloud Tier 3 AI infrastructure powered by NVIDIA B200 and B300 chips [9]. - The company plans to accelerate the manufacturing and global distribution of its ARMS 200 pods [9]. - The financing will support strategic joint ventures and PPA-backed energy deployments, as well as non-dilutive financing initiatives [9]. Market Position - The offering reflects a growing interest in the company's scalable AI infrastructure strategy, particularly its proprietary ARMS 200 Tier 3 modular data center platform and NeoCloud GPU-as-a-Service infrastructure [3][9]. - Titan Partners Group is acting as the sole placement agent for this offering [4].

Core Viewpoint - Quest Diagnostics is a strong candidate for investors looking for stocks that consistently beat earnings estimates and may continue this trend in the upcoming quarterly report [1] Group 1: Earnings Performance - Quest Diagnostics has a strong track record of surpassing earnings estimates, averaging a 2.31% beat over the last two quarters [2] - In the last reported quarter, the company achieved earnings of $2.21 per share, exceeding the Zacks Consensus Estimate of $2.15 per share by 2.79% [3] - In the previous quarter, Quest Diagnostics reported earnings of $2.23 per share against an expected $2.19, resulting in a surprise of 1.83% [3] Group 2: Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Quest Diagnostics, with a positive Earnings ESP (Expected Surprise Prediction) indicating potential for an earnings beat [6] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7] - Quest Diagnostics currently has an Earnings ESP of +0.17%, suggesting analysts are optimistic about its near-term earnings potential [9]

Core Viewpoint - Digi Power X Inc. has executed a purchase order with Super Micro Computer, Inc. to supply NVIDIA B200-powered systems for the launch of its NeoCloud AI infrastructure platform, marking a significant step towards revenue generation in the AI sector [1][3]. Group 1: Company Developments - The Supermicro systems will be deployed in Digi Power X's ARMS 200 pods, with the first deployment scheduled for the Alabama site in Q4 2025 [2]. - The company aims to generate substantial recurring revenue through high-performance GPU cloud rentals, with each megawatt of Tier 3 AI infrastructure expected to contribute significantly [3]. - Digi Power X is advancing the design of the ARMS 300 platform, targeting a total of 55 megawatts of Tier 3 AI infrastructure by 2026-2027 [4]. Group 2: Financial Strategy - The company plans to finance its growth through non-dilutive debt, leveraging platform-driven AI compute revenue to ensure predictable cash flow and strong margins while retaining full equity for shareholders [4]. - The business model is designed for a sub-three-year payback period, indicating a focus on financial efficiency and shareholder value [4]. Group 3: Market Positioning - Digi Power X is positioning itself as a first mover in the AI infrastructure market, aiming to deploy and monetize NVIDIA's Blackwell architecture at cloud scale [5]. - Following the Alabama deployment, additional ARMS 200 systems are planned for Upstate New York, indicating a strategic expansion of operations [5]. Group 4: Company Overview - Digi Power X is a vertically integrated AI and energy infrastructure company that designs and deploys modular Tier 3 data centers and offers enterprise-grade GPU compute through its NeoCloud portal [6].

Company Overview - Quest Diagnostics Inc. is headquartered in Secaucus, New Jersey, providing diagnostic information services to a wide range of customers, including physicians, hospitals, and patients [11] - The company serves Independent Delivery Networks (IDN) across the United States through its Professional Lab Services (PLS), focusing on improving quality and reducing healthcare costs [11] Zacks Rank and Style Scores - Quest Diagnostics has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12] - The Value Style Score for Quest Diagnostics is B, supported by a forward P/E ratio of 17.35, making it attractive for value investors [12] - The Zacks Consensus Estimate for fiscal 2025 earnings has increased to $9.70 per share, with one analyst revising their estimate upwards in the last 60 days [12] Investment Potential - With a strong Zacks Rank and favorable Value and VGM Style Scores, Quest Diagnostics is recommended for investors' consideration [13]

Core Insights - Quest Diagnostics has launched a new diagnostic laboratory test for the Oropouche virus, an emerging disease prevalent in South and Central America and the Caribbean [1][2]. Company Developments - The new test will be available by prescription for clinical purposes by the end of the month, utilizing polymerase chain reaction (PCR) technology for early-stage diagnosis, with serology testing to follow later this quarter [3]. - Quest Diagnostics was awarded contracts by the U.S. Centers for Disease Control and Prevention (CDC) in September 2024 to support testing and laboratory readiness for emerging infectious diseases, including the Oropouche virus [4]. Industry Context - The Oropouche virus is transmitted by infected biting midges and some mosquito species, with a low current threat level in North America, primarily affecting travelers returning from endemic regions [2]. - The virus can cause severe neuroinvasive diseases such as meningitis and encephalitis, although most individuals recover without intervention [2].